A dual therapy of off-pump temporary left ventricular extracorporeal device and amniotic stem cell for cardiogenic shock

Toshinobu Kazui 1,2,6†, Phat L. Tran 2,5†, Tia R. Pilikian 1, Katie M. Marsh 1,2, Raymond Runyan 3, John Konhilas 3, Richard Smith 5 and Zain I. Khalpey 1,2,3,4,5,6*

Abstract

Background: Temporary mechanical circulatory support device without sternotomy has been highly advocated for severe cardiogenic shock patient but little is known when coupled with amniotic stem cell therapy.

Case presentation: This case reports the first dual therapy of temporary left ventricular extracorporeal device CentriMag with distal banding technique and human amniotic stem cell injection for treating a severe refractory cardiogenic shock of an 68-year-old female patient. A minimally-invasive off-pump LVAD was established by draining from the left ventricle and returning to the right axillary artery with distal arterial banding to prevent right upper extremity hyperperfusion. Amniotic stem cells were injected intramyocardially at the left ventricular apex, lateral wall, inferior wall, and right subclavian vein.

Conclusion: The concomitant use of the temporary minimally-invasive off-pump CentriMag placement and stem cell therapy not only provided an alternative to cardiopulmonary bypass and full-median sternotomy procedures but may have also synergistically enhanced myocardial reperfusion and regeneration.

Keywords: Off-pump, Extracorporeal device, Left Ventricular Assist Device (LVAD), Refractory Cardiogenic Shock (RCS), Amniotic stem cell

Background

Severe refractory cardiogenic shock (RCS) can be defined as significant left or right ventricular dysfunction resulting in sustained hypotension and hypoperfusion of end-organs. Treatment for RCS would include one or more modalities like pharmaco-agents (inotropes and vasopressors), intra-aortic balloon pump (IABP), revascularization in the case of myocardial infarction, and ultimately mechanical circulatory support (MCS) system to hemodynamically unload the heart and restore circulation. One of such MCS system is the centrifugal pumps like CentriMag (Thoratec Corp, Pleasanton, CA), Rotaflow (MAQUET Cardiopulmonary AG, Hirrlingen, Germany), or Sorin Revolution (Sorin Group USA, Inc., Arvada, CO). These temporary ventricular assist devices (VAD) have been widely used as bridge-to-decision or bridge-to-recovery in patients with refractory cardiogenic shock [1, 2]. However, cardiac recovery leading to VAD explantation is still observed in a very small population [3].

Most of patients who require this therapy fall into INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profile1. Conventionally, the temporary left VAD implantation has been performed through median sternotomy with or without cardiopulmonary bypass (CPB) support. These critically ill patients tend to bleed more during and after surgery for pre-operative liver dysfunction [4]. Especially for patient with previous sternotomy, the dissection can take longer and bleed more.

Patients with VAD may also be benefited from stem cell therapy (SCT), which has been shown to potentially increase circulatory perfusion [5, 6], promote angiogenesis and reduction of fibrin formation after VAD.
implantation [7], and improve ejection fraction (EF) [8].

More particularly, Nasseri et al. [5] looked at 10 patients on long-term left ventricular assist device (LVAD) concomitantly injected with bone marrow mononuclear cells. They found one improved cardiac function resulting in LVAD explantation, 2 deaths, and 7 others exhibited increased perfusion. However, these case reports and series are utilizing long-term LVAD support platform with maximal inflammation induction from median sternotomy; therefore creating an unfavorable environment for stem cell engraftment and differentiation that may potentially hinder cardiac recovery.

To recover the heart, a minimally invasive approach with stem cell therapy was applied to reduce surgical insult, avoiding CPB pump and median sternotomy. We cannulated at the apex of the left ventricle and returned through the right axillary artery with distal banding technique to avoid hyperperfusion. We then administered a bi-modal delivery of amniotic stem cells with the intention of initiating cellular myocardial recovery.

**Case presentation**

A 68-year-old female patient with past medical history of, two previous coronary artery bypass grafts, hypertension, chronic kidney disease, and diabetes mellitus, presented to a local hospital with chest pain and shortness of breath following an ST-elevation myocardial infarction. The patient was placed on an IABP and underwent a cardiac catheterization with the placement of five stents in the left anterior descending artery and saphenous vein graft. However she developed postoperative cardiogenic shock and multi-organ hypoperfusion despite her IABP and increased pressor requirements. She was then transferred to our institution for possible ventricular assist device placement.

Preoperative transesophageal echocardiography (TEE) demonstrated EF of 10% with apical akinesis, mild aortic insufficiency, moderate mitral and tricuspid valve regurgitation. Right heart was functional prompting for a CentriMag LVAD placement as Bridge-to-Decision/Recovery.

The patient was placed supine position. The position of Left ventricular (LV) apex was confirmed by trans-thoracic echocardiography. A 5 cm mini-thoracotomy at 5th intercostal space was made. A pericardial well was created and A Thoratec 34 Fr inflow cannula (Thoratec Corp, Pleasanton, CA) was brought to the field. The Thoratec cuff was sewn into the left ventricular apex using plegetted 3–0 Ethibond sutures followed by a running 3–0 Prolene suture. The right axillary artery was exposed. Activated clotting time guided heparin was confirmed to be more than 200 s. An 8 mm Dacron graft was sewn into the axillary artery in end-to-side fashion using a 4–0 Prolene running suture. A 20 Fr EOPA cannula was passed through the graft with the tip extending to the level of the anastomosis. Silk ties were used to secure the cannula to the graft. The distal axillary artery was banded with a vessel loop. Banding prevented arterial and right axillary artery distal from over perfusion and ensured adequate cerebral perfusion. Remaining off-pump, the 34 Fr Thoratec inflow cannula was passed into the left ventricle. The position was confirmed by TEE. The cannula was secured to the cuff and was de-aired and connected to the CentriMag device (Fig. 1). The CentriMag was started and flow was established at 4.5 L/min. Human allograft and liquid matrix was inserted into the subclavian vein (2 times of 1 cm³ of PalinGen Kardia Flow, Amnio Technology, Phoenix, AZ, USA) and into the anterior, lateral, and inferior walls of the LV (1 cm³ of PalinGen Kardia Flow each).

Her end organ function recovered during the support. Transthoracic Echocardiography (TTE) was conducted which showed LV recovery, EF 30% with 1.5 LPM of LVAD flow at post op day 13. At post op day 20, fibrin clots developed in both the inflow and outflow cannula connectors prompting for an urgent decannulation at post op day 21. Upon off-pump LVAD removal, a subsequent IABP was placed and inotropic support was started in an effort to increase coronary perfusion. A head CT scan showed evidence of a small right sided ischemic cerebral infarct possibly due to clots dislodgement from the support/plumbing system or thrombotic occlusion of the right brachiocephalic trunk, right common carotid, right internal, and right vertebral arteries resulting in left sided hemiplegia. Extubation, IABP removal, and

![Fig. 1 Application of the Thoratec® CentriMag® LVAD with inflow cannulation from the left ventricular apex, outflow cannulation via 8 mm Dacron graft into the right axillary artery, and arterial banding distal to outflow](image-url)
BiPAP administration was performed on post-explant day three. The patient was discharge to rehabilitation facility.

Conclusion
With regard to implantable LVAD, off pump placement has been reported [9]. However, to our best knowledge, this is the first dual therapy of using a temporary off-pump implantation of a CentriMag as a left ventricular extracorporeal device with banding technique and human amniotic stem cell. CentriMag LVAD placement was performed in an off-pump fashion with left minithoracotomy and adjusted distal arm flow by placing a tourniquet. This is a viable short-term solution as bridge to decision/recovery especially for patients with previous sternotomy. Also, anastomosis of a graft to the right axillary artery can further prevent complications relating to direct axillary artery cannulation. This approach gave us a flexibility to extubate and to mobilize the patient while she was on the support. Avoiding the usage of CPB and full sternotomy can also minimize postoperative inflammation, preserve end organ function, and potentially prevent RV dysfunction [10].

One of the potential disadvantages of this approach was hyperperfusion of the right arm and right carotid artery. We were able to avoid the latter complication by tightening the axillary artery distal to the anastomosed site via a tourniquet such that the right radial pressure matched the left radial pressure upon stable support.

From the hemodynamic point of view, mechanically unloading the heart has been shown to increase survivability and promote differentiation of cardiac stem cells injected in the myocardium of an infarcted animal heart [11]; inhibit apoptotic mechanism and facilitated stem cells engraftment in a mouse model [12]. It appears that our minimally invasive off pump approach minimizes sternotomy-induced myocardial inflammation, reduces myocardial load, improves coronary perfusion such that a favorable environment was created for amniotic stem cell to engraft and resurrect the ailing heart. In fact, our patient’s left ventricle EF improved from 10 to 30% by postop day 13. This observed clinical improvement is concurrent to bone marrow stem cell studies reported by Gojo et al. [8] (EF improved from 6.4 to 40%) and Miyagawa et al. [13] (EF improved from 22 to 32%). Aside from safe to use, we think that direct stem cell injection may provide myocardial functional recovery but further study is highly warranted in the future. The concomitant use of SCT and LVAD have been previously reported by Dib et al. [14] and Pagani et al. [15]. However, they were using skeletal myoblasts, which is less versatile than amniotic stem cells and long term LVAD, which can inflict maximal surgical insults. Our minimally-invasive off-pump CentriMag LVAD placement has the potential to achieve shorter recovery times and improve clinical outcomes in profound RCS and previous cardiac surgery patients. Finally, we further demonstrated that dual therapy of LVAD and SCT is also feasible, safe, and may be efficacious to LVAD explantation; thus moving toward a more prescriptive/individualized medical therapy for early and end stage heart failure patients.

Abbreviations
CPB: CardioPulmonary Bypass; EF: Ejection fraction; IABP: Intra-aortic balloon pump; LV: Left ventricle; LVAD: Left ventricular assist device; MCS: Mechanical circulatory support; RCS: Refractory cardiogenic shock; SCT: Stem cell therapy; TEE: TransEsophageal Echocardiography; TTE: TransThoracic Echocardiography; VAD: Ventricular assist devices

Acknowledgements
The authors thank the OR and ICU staff.

Funding
Authors have no funding to disclose.

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
TK, PLT, KM, RS, and ZK were members of the surgical team. PLT, TRP, RR, and JK were involved in drafting and critical revisions. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Department of Surgery, Division of Cardiothoracic Surgery, University of Arizona, Tucson, AZ, USA. 2. College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA. 3. Department of Physiological Sciences, University of Arizona, Tucson, AZ, USA. 4. Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA. 5. Artificial Heart Program, Banner University Medical Center, Tucson, AZ, USA. 6. Division of Cardiothoracic Surgery, Banner University Medical Center Tucson, 1501 N Campbell Ave, Rm 4302A, P.O. Box 245071, Tucson, AZ 85724-5071, USA.

Received: 29 March 2017 Accepted: 29 August 2017

Published online: 07 September 2017

References
1. Takayama H, Soni L, Kalesan B, Truby LK, Ota T, Cedola S, et al. Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory Cardiogenic shock of various causes. Circ Hear Fail. 2014;7:799–806.
2. Shalhaber JH, Jenkins D, Berman M, Parameshwar J, Dhillt K, Tsui S, et al. The Papworth experience with the Levitronix CentriMag ventricular assist device. J. Hear. Lung Transplant. 2008;27:158–64.
3. Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation. 1998;98:2383–9.
4. Bhama JK, Kornos RL, Toyoda Y, Teuteberg JJ, McCurry KR, Siegenthaler MP. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J. Hear. Lung Transplant. 2009;28:971–6.

5. Nasseri BA, Kukucka M, Dandel M, Krosalla C, Potapov E, Lehmkuhl HB, et al. Intramyocardial delivery of bone marrow mononuclear cells and mechanical assist device implantation in patients with end-stage cardiomyopathy. Cell Transplant. 2007;16:941–9.

6. Anastasiadis K, Antonitsis P, Angiriadou H, Kolakis G, Doumas A, Khayat A, et al. Hybrid approach of ventricular assist device and autologous bone marrow stem cells implantation in end-stage ischemic heart failure enhances myocardial reperfusion. J Transl Med. 2011;9:12.

7. Memon IA, Sawa Y, Miyagawa S, Taketani S, Matsuda H. Combined autologous cellular cardiomyoplasty with skeletal myoblasts and bone marrow cells in canine hearts for ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2005;130:646–53.

8. Gojo S, Kyo S, Nishimura S, Komiyama N, Kawai N, Bebso M, et al. Cardiac resurrection after bone-marrow-derived mononuclear cell transplantation during left ventricular assist device support. Ann Thorac Surg. 2007;83:661–2.

9. Sileshi B, Haglund NA, Davis ME, Tricarico NM, Stulak JM, Khasho Z, et al. In-hospital outcomes of a minimally invasive off-pump left thoracotomy approach using a centrifugal continuous-flow left ventricular assist device. J Hear Lung Transplant. 2015;34:107–12.

10. Strueber M, Meyer AL, Feussner M, Ender J, Correa J-C, Mohr F-W. A minimally invasive off-pump implantation technique for continuous-flow left ventricular assist devices: early experience. J Heart Lung Transplant. 2014;33:851–6.

11. Kurazumi H, Li T, Takemoto Y, Suzuki R, Mikamo A. Haemodynamic unloading increases the survival and affects the differentiation of cardiac stem cells after implantation into an infarcted heart. Eur J Cardiothorac Surg. 2014;45:976–82.

12. Suzuki R, Li TS, Mikamo A, Takahashi M, Ohsima M, Kubo M, et al. The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment. J Thorac Cardiovasc Surg. 2007;133:1051–8.

13. Miyagawa S, Matsumiya G, Funatsu T, Yoshitatsu M, Sekiya N, Fukui S, et al. Combined autologous cellular cardiomyoplasty using skeletal myoblasts and bone marrow cells for human ischemic cardiomyopathy with left ventricular assist system implantation: report of a case. Surg Today. 2009;39:133–6.

14. Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation. 2005;112:748–55.

15. Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge ASB, Jacoby D, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans: histological analysis of cell survival and differentiation. J Am Coll Cardiol. 2003;41:879–88.